References
1. Myers MF, Chang M-H, Jorgensen C, et al. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices. Genet Med 2006;8:361–370.
2. Janssens CJW, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalized health interventions. Am J Hum Genet 2008;82:593–599.
3. Magnus D, Cho M, Cook-Deegan B. Direct-to-consumer genetic tests: beyond medical regulation? Genome Med 2009;1:17.
4. Eng C, Sharp R. Bioethical and clinical dilemmas of direct-to-consumer personal genomic testing: the problem of misattributed equivalence. Sci Transl Med 2010;2(17):17cm5.
5. Khoury MJ, McBride CM, Schully SD, et al. Centers for Disease Control and Prevention. The scientific foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009;11:559–567.
6. Wacholder S, Haretge P, Prentice R. Performance of common genetic variants in breast cancer risk models. N Engl J Med 2010;363:986–993.
7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–1333.
8. Mealiffe M, Stokowski R, Thees B, Prentice R, Pettinger M, Hinds D. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst 2010;102:1618–1627.
9. deCODE Genetics Web site. http://www. decode.com. Accessed March 13, 2011.
10. 23andME Web site. http://www.23andMe. com. Accessed March 13, 2011.
11. Navigenics Web site. http://www.navigenics. com. Accessed March 13, 2011.
12. Proactive Genomics Web site. http:// www.proactivegenomics.com. Accessed March 13, 2011.
13. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009;461:724–726.
14. GAO report: Direct-to-consumer genetic tests: misleading test results are further complicated by deceptive marketing and other questionable practices. GAO-10-847T July 22, 2010. http://www.gao.gov/products/GAO-10- 847T. Accessed March 13, 2011.
15. Udesky L. The ethics of direct-to-consumer genetic testing. Lancet 2010;376:1377– 1378.
16. Berndt S, Platz E, Fallin M. Mismatch repair polymorphism and the risk of colorectal cancer. Int J Cancer 2007;120:1548–1554.
17. da Silva TD, Felipe AV, de Lima JM, Oshima CT, Forones NM. N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer. World J Gastroenterol 2011;17:760– 765.
18. Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 2008;9:161–182.
19. Gray S, Olopade OI. Direct-to-consumer marketing of genetics tests for cancer: buyer beware. J Clin Oncol 2003;21:3191– 3193.
20. Gollust SE, Chandros Hull S, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762–1767.
21. Wolfberg AJ. Genes on the Web: directto- consumer marketing of genetic testing. N Engl J Med 2006;355:543–545.
22. European Society of Human Genetics. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 2010;18:1271–1273.
23. Williams-Jones B. “Be ready against cancer, now”: direct-to-consumer advertising for genetic testing. New Genet Soc 2006;25:89–107.
24. Kolar K, Liu T, St Pierre J, Khoury MJ. Heath care provider and consumer awareness, perceptions, and use of direct-to-consumer personal genomic tests. Genet Med 2009;11:595.
25. McGuire AL, Diaz C, Wang T, et al. Social networkers’ attitudes toward direct-toconsumer personal genome testing. Am J Bioethics 2009;9:3–10.
26. McGuire AL, Burke W. An unwelcome side effect of direct-to consumer personal genome testing: raiding the medical commons. JAMA 2008;300:2669–2671.
27. Caufield T, Ries NM, Ray PN, Shuman C, Wilson B. Direct-to-consumer genetic testing: good, bad or benign? Clin Genetic 2010;77:101–105.
28. Mykitiuk R. Caveat emptor: direct-toconsumer supply and advertising of genetic testing. Clin Invest Med 2004;27:23–32.
29. American College of Medical Genetics (ACMG) statement on direct-to-consumer genetic testing: April 7, 2008. http://www. acmg.net/AM/Template.cfm?Section=Policy_ Statements&Template=/CM/ContentDisplay. cfm&ContentID=2975, Accessed March 13, 2011.
30. Hudson K, Javitt G, Burke W. ASHG statement on direct-to-consumer genetic testing in the United States. Obstet Gynecol 2007;110:1392–1395.
31. NSGC statement on direct to consumer genetic testing. Adopted 2007. http://www. nsgc.org/Media/PositionStatements/tabid/ 330/Default.aspx#DTC. Accessed March 13, 2011.
32. AMA Press Release, February 23, 2011. AMA to FDA: genetic testing should be conducted by qualified health professionals. http:// www.ama-assn.org/ama/pub/news/news/genetic- testing-qualified-professionals.page. Accessed March 8, 2011.
33. Annes JP, Giovanni MA, Murray MF. Risk of presymptomatic direct-to-consumer genetic testing. N Engl J Med 2010;363:1100–1101.